Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1576-1582

  Kefala, Maria ^a   Papageorgiou, Sotirios G ^a   Kontos, Christos K ^b   Economopoulou, Panagiota ^a   Tsanas, Athanasios ^c   Pappa, Vasiliki ^a   Panayiotides, Ioannis G ^a   Gorgoulis, Vassilios G ^a   Patsouris, Eustratios ^a   Foukas, Periklis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

H2AX; DNA damage response; Myelodysplastic syndromes; PATM; PNBS1

Indexed keywords

ATM PROTEIN; HISTONE H2AX; NIBRIN; PROTEIN GAMMA H2AX; PROTEIN P53; PROTEIN PATM; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER PROGNOSIS; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RISK ASSESSMENT; RISK FACTOR; UPREGULATION;

ΓH2AX; DNA DAMAGE RESPONSE; MYELODYSPLASTIC SYNDROMES; PATM; PNBS1;

ADULT; AGED; AGED, 80 AND OVER; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL CYCLE PROTEINS; CYTOGENETIC ANALYSIS; DNA DAMAGE; FEMALE; FOLLOW-UP STUDIES; HISTONES; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886775630     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.018     Document Type: Article

References (39)

1. Swerdlow S. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 88-93. Lyon. 4th ed.
2. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Pozdnyakova O., Miron P.M., Tang G., Walter O., Raza A., Woda B., et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008, 113:3331-3340.
4. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 2001, 73:429-437.
5. Jeggo P.A., Lobrich M. DNA double-strand breaks: their cellular and clinical impact. Oncogene 2007, 26:7717-7719.
6. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
7. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3932-3938.
8. Wang Y.Y., Cen J.N., He J., Shen H.J., Liu D.D., Yao L., et al. Accelerated cellular senescence in myelodysplastic syndrome. Exp Hematol 2009, 37:1310-1317.
9. Uziel T., Lerenthal Y., Moyal L., Andegeko Y., Mittelman L., Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003, 22:5612-5621.
10. Economopoulou P., Pappa V., Papageorgiou S., Dervenoulas J., Economopoulos T. Abnormalities of DNA repair mechanisms in common hematological malignancies. Leuk Lymphoma 2011, 52:567-582.
11. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
12. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
13. Oka K., Tanaka T., Enoki T., Yoshimura K., Ohshima M., Kubo M., et al. DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther 2010, 9:246-252.
14. Koorstra J.B., Hong S.M., Shi C., Meeker A.K., Ryu J.K., Offerhaus G.J., et al. Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Mod Pathol 2009, 22:1439-1445.
15. Horibe S., Takagi M., Unno J., Nagasawa M., Morio T., Arai A., et al. DNA damage check points prevent leukemic transformation in myelodysplastic syndrome. Leukemia 2007, 21:2195-2198.
16. Boehrer S., Ades L., Tajeddine N., Hofmann W.K., Kriener S., Bug G., et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009, 28:2205-2218.
17. Economopoulou P., Pappa V., Kontsioti F., Papageorgiou S., Foukas P., Liakata E., et al. Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. Ann Hematol 2010, 89:233-239.
18. Schreck R. Curr Protoc Hum Genet. Appendix 4: Appendix 4B.
19. Camp R.L., Dolled-Filhart M., Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-7259.
20. Redon C.E., Dickey J.S., Nakamura A.J., Kareva I.G., Naf D., Nowsheen S., et al. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci USA 2010, 107:17992-17997.
21. Head D.R., Jacobberger J.W., Mosse C., Jagasia M., Dupont W., Goodman S., et al. Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis. Bone Marrow Res 2011, 2011:950934.
22. Delia D., Aiello A., Soligo D., Fontanella E., Melani C., Pezzella F., et al. bcl-2 Proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992, 79:1291-1298.
23. Tsoplou P., Kouraklis-Symeonidis A., Thanopoulou E., Zikos P., Orphanos V., Zoumbos N.C. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia 1999, 13:1554-1563.
24. Novotna B., Neuwirtova R., Siskova M., Bagryantseva Y. DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts. Hum Mol Genet 2008, 17:2144-2149.
25. Ito H., Miller S.C., Billingham M.E., Akimoto H., Torti S.V., Wade R., et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990, 87:4275-4279.
26. Kurabayashi M., Jeyaseelan R., Kedes L. Antineoplastic agent doxorubicin inhibits myogenic differentiation of C2 myoblasts. J Biol Chem 1993, 268:5524-5529.
27. Lebrun P., Montminy M.R., Van Obberghen E. Regulation of the pancreatic duodenal homeobox-1 protein by DNA-dependent protein kinase. J Biol Chem 2005, 280:38203-38210.
28. Puri P.L., Bhakta K., Wood L.D., Costanzo A., Zhu J., Wang J.Y. A myogenic differentiation checkpoint activated by genotoxic stress. Nat Genet 2002, 32:585-593.
29. Simonatto M., Latella L., Puri P.L. DNA damage and cellular differentiation: more questions than responses. J Cell Physiol 2007, 213:642-648.
30. Weaver B.A., Silk A.D., Montagna C., Verdier-Pinard P., Cleveland D.W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007, 11:25-36.
31. Duesberg P., Rausch C., Rasnick D., Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 1998, 95:13692-13697.
32. Maeck L., Haase D., Schoch C., Hiddemann W., Alves F. Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations. Br J Haematol 2000, 109:842-846.
33. Sheltzer J.M., Torres E.M., Dunham M.J., Amon A. Transcriptional consequences of aneuploidy. Proc Natl Acad Sci USA 2012, 109:12644-12649.
34. Chiang Y.C., Teng S.C., Su Y.N., Hsieh F.J., Wu K.J. c-Myc directly regulates the transcription of the NBS1 gene involved in DNA double-strand break repair. J Biol Chem 2003, 278:19286-19291.
35. Yang M.H., Chiang W.C., Chou T.Y., Chang S.Y., Chen P.M., Teng S.C., et al. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res 2006, 12:507-515.
36. Follo M.Y., Mongiorgi S., Bosi C., Cappellini A., Finelli C., Chiarini F., et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007, 67:4287-4294.
37. Ehlers J.P., Harbour J.W. NBS1 expression as a prognostic marker in uveal melanoma. Clin Cancer Res 2005, 11:1849-1853.
38. Bartkova J., Tommiska J., Oplustilova L., Aaltonen K., Tamminen A., Heikkinen T., et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008, 2:296-316.
39. Rink L., Slupianek A., Stoklosa T., Nieborowska-Skorska M., Urbanska K., Seferynska I., et al. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood 2007, 110:651-660.